Neurocrine Biosciences Inc. (NBIX) bad FDA but

G

gimp570

Neurocrine Biosciences Inc. (NBIX)


bad news but its only down a little after hours

i wonder why? anyone have any ideas



Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated.





i wonder why? anyone have any ideas
 
i guess we have to wait until wednesday...either the news is not important or after hours is a bunch of bull



either way i wont get much sleep
 
for that bad of news...NBIX could not be having a better day

well its either a super strong stock that can shrug off bad news...which are the stocks that can change your life style

or

that drug trial was a long shot to be good and everyone knew it...



i dont know????




Quote from gimp570:

Neurocrine Biosciences Inc. (NBIX)


bad news but its only down a little after hours

i wonder why? anyone have any ideas



Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated.





i wonder why? anyone have any ideas
More...
 
Quote from gimp570:

some one knows something....



sit back and let it ride...these bios can really run



NBIX
More...


well i guess this is why it was up last week


8:01AM Neurocrine Biosci announces that VMAT2 program will move into Phase II clinical trials (NBIX) 8.04 : Co announces that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the VMAT2 program to initiate Phase II studies.
 
Neurocrine Biosciences Inc. (NBIX)-


I have been waiting for big news Good or Bad for a long time now....something big has to come out sooonnn



At this point i just want big news.....


Anyone know of anytime frames for these drug trials to be complete??
 
i guess i will just keep on waiting




Quote from gimp570:

Neurocrine Biosciences Inc. (NBIX)-


I have been waiting for big news Good or Bad for a long time now....something big has to come out sooonnn



At this point i just want big news.....


Anyone know of anytime frames for these drug trials to be complete??
More...
 
You must log in or register to reply here.
Back
Top